CAS 1952251-28-3

TAK-659 hydrochloride

CAS : 1952251-28-3

Formule : C₁₇H₂₂ClFN₆O

Degré de pureté : 99%

Couleur et forme : Solid

Masse moléculaire : 380.8476

Ref: IN-DA01EN3F

6-(((1R,2S)-2-Aminocyclohexyl)Amino)-7-Fluoro-4-(1-Methyl-1H-Pyrazol-4-Yl)-1,2-Dihydro-3H-Pyrrolo[3,4-C]Pyridin-3-One Hydrochloride

CAS : 1952251-28-3

6-(((1R,2S)-2-Aminocyclohexyl)Amino)-7-Fluoro-4-(1-Methyl-1H-Pyrazol-4-Yl)-1,2-Dihydro-3H-Pyrrolo[3,4-C]Pyridin-3-One Hydrochloride

Degré de pureté : 99%

Masse moléculaire : 380.85g/mol

Ref: 54-PC108718

TAK-659 hydrochloride

CAS : 1952251-28-3

TAK-659 hydrochloride

Degré de pureté : ≥98%

Masse moléculaire : 380.85g/mol

Ref: 54-BUP01641

TAK-659 hydrochloride

CAS : 1952251-28-3

TAK-659 hydrochloride (TAK-659) is a potent and selective inhibitor of spleen tyrosine kinase (SYK) with an IC50 value of 3.2 nM.

Formule : C₁₇H₂₂ClFN₆O

Degré de pureté : 99.28% - 99.82%

Couleur et forme : Solid

Masse moléculaire : 380.85

Ref: TM-T4209

TAK-659

CAS : 1952251-28-3

TAK-659 is a small molecule that has been shown to be highly selective for the epidermal growth factor receptor (EGFR). It inhibits the phosphorylation of EGFR and subsequent downstream signaling through protein kinases. TAK-659 may be used for the treatment of autoimmune diseases, including psoriasis, rheumatoid arthritis, and Crohn's disease. In addition, this drug has been shown to inhibit platelet aggregation and to stimulate hematopoietic cells in cancer patients. TAK-659 is also being investigated as a potential drug for the treatment of cancer due to its ability to inhibit cellular transformation.

Formule : C₁₇H₂₁FN₆·HCl

Degré de pureté : Min. 95%

Masse moléculaire : 380.85 g/mol

Ref: 3D-CDD25128